Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 70

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 70
---
 sales, marketing and distribution efforts of our product
candidates. There can be no assurance that we will be able to develop internal sales, marketing distribution capabilities or establish
or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.

We face substantial competition from other
pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.

The development and commercialization
of new drug products is highly competitive. We expect that we will face significant competition from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide with respect to our DN-TNF product platform, INKmune and any other of our
product candidates that we may seek to develop or commercialize in the future. Specifically, due to the large unmet medical need, global
demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely competitive and there are a number of large
pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates
for the treatment of cancer. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are
more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing
or that we may develop, which could render our product candidates obsolete and noncompetitive.

41

We rely on key personnel and, if we are
unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow effectively.

We are dependent on certain
members of our management, the loss of services of one or more of whom could materially adversely affect us. In particular, our success
depends to a significant extent upon the continued services of Dr. Raymond J. Tesi, our President and CEO. Dr. Tesi has overseen INmune
Bio since inception and provides leadership for our growth and operations strategy as well as being an inventor of our patents. Although
we have entered into an employment agreement with Dr. Tesi, if he were to nevertheless terminate his employment with us, the loss of the
services of Dr. Tesi, would have a material adverse effect on our growth, revenues, and prospective business. We are also highly dependent
on the other principal members of our management and scientific team. We are not aware of any present intention of any of our key personnel
to leave our company or to retire. The loss of any of our key personnel, or the inability to attract and retain qualified personnel,